Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.

Article  PubMed  Google Scholar 

Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376:354–66.

Article  CAS  PubMed  Google Scholar 

Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, Gore JL, Sun M, Wood C, Russo P. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75:74–84.

Article  PubMed  Google Scholar 

Atkins MB, Tannir NM. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. Cancer Treat Rev. 2018;70:127–37.

Article  CAS  PubMed  Google Scholar 

Tacconi EMC, Tuthill M, Protheroe A. Review of adjuvant therapies in renal cell carcinoma: evidence to date. Onco Targets Ther. 2020;13:12301–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mattei J, da Silva RD, Sehrt D, Molina WR, Kim FJ. Targeted therapy in metastatic renal carcinoma. Cancer Lett. 2014;343:156–60.

Article  CAS  PubMed  Google Scholar 

Lalani AA, McGregor BA, Albiges L, Choueiri TK, Motzer R, Powles T, Wood C, Bex A. Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: current paradigms, use of immunotherapy, and future directions. Eur Urol. 2019;75:100–10.

Article  PubMed  Google Scholar 

Dos Santos M, Brachet PE, Chevreau C, Joly F. Impact of targeted therapies in metastatic renal cell carcinoma on patient-reported outcomes: methodology of clinical trials and clinical benefit. Cancer Treat Rev. 2017;53:53–60.

Article  PubMed  Google Scholar 

Flippot R, Escudier B, Albiges L. Immune checkpoint inhibitors: toward new paradigms in renal cell carcinoma. Drugs. 2018;78:1443–57.

Article  CAS  PubMed  Google Scholar 

Diaz-Montero CM, Rini BI, Finke JH. The immunology of renal cell carcinoma. Nat Rev Nephrol. 2020;16:721–35.

Article  PubMed  Google Scholar 

Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthelemy P, Porta C, George S, Powles T, Donskov F, Neiman V, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pan JH, Zhou H, Cooper L, Huang JL, Zhu SB, Zhao XX, Ding H, Pan YL, Rong L. LAYN is a prognostic biomarker and correlated with immune infiltrates in gastric and colon cancers. Front Immunol. 2019;10:6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang F, Cao X, Yin L, Wang Q, He Z. Identification of SCARA5 gene as a potential immune-related biomarker for triple-negative breast cancer by integrated analysis. DNA Cell Biol. 2020;39:1813–24.

Article  CAS  PubMed  Google Scholar 

Koliaraki V, Prados A, Armaka M, Kollias G. The mesenchymal context in inflammation, immunity and cancer. Nat Immunol. 2020;21:974–82.

Article  CAS  PubMed  Google Scholar 

Singh R, Mishra MK, Aggarwal H. Inflammation, immunity, and cancer. Mediat Inflamm. 2017;2017:6027305.

Article  Google Scholar 

Weber R, Groth C, Lasser S, Arkhypov I, Petrova V, Altevogt P, Utikal J, Umansky V. IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy. Cell Immunol. 2021;359: 104254.

Article  CAS  PubMed  Google Scholar 

Im JH, Buzzelli JN, Jones K, Franchini F, Gordon-Weeks A, Markelc B, Chen J, Kim J, Cao Y, Muschel RJ. FGF2 alters macrophage polarization, tumour immunity and growth and can be targeted during radiotherapy. Nat Commun. 2020;11:4064.

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Mantovani A, Ponzetta A, Inforzato A, Jaillon S. Innate immunity, inflammation and tumour progression: double-edged swords. J Intern Med. 2019;285:524–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pflug KM, Sitcheran R. Targeting NF-kappaB-inducing kinase (NIK) in immunity, inflammation, and cancer. Int J Mol Sci. 2020;21:8470.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu Y, Li L, Li Y, Zhao X. Research progress on tumor-associated macrophages and inflammation in cervical cancer. Biomed Res Int. 2020;2020:6842963.

PubMed  PubMed Central  Google Scholar 

Luoma AM, Suo S, Williams HL, Sharova T, Sullivan K, Manos M, Bowling P, Hodi FS, Rahma O, Sullivan RJ, Boland GM, Nowak JA, Dougan SK, et al. Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell. 2020;182(655–71): e22.

Google Scholar 

Fest J, Ruiter R, Mulder M, Groot Koerkamp B, Ikram MA, Stricker BH, van Eijck CHJ. The systemic immune-inflammation index is associated with an increased risk of incident cancer—a population-based cohort study. Int J Cancer. 2020;146:692–8.

Article  CAS  PubMed  Google Scholar 

Huang H, Liu Q, Zhu L, Zhang Y, Lu X, Wu Y, Liu L. Prognostic value of preoperative systemic immune-inflammation index in patients with cervical cancer. Sci Rep. 2019;9:3284.

Article  ADS  PubMed  PubMed Central  Google Scholar 

Zhang L, Zhang B, Wei M, Xu Z, Kong W, Deng K, Xu X, Zhang L, Zetahao X, Yan L. TRIM22 inhibits endometrial cancer progression through the NOD2/NFkappaB signaling pathway and confers a favorable prognosis. Int J Oncol. 2020;56:1225–39.

CAS  PubMed  PubMed Central  Google Scholar 

Zhou Y, Hu L, Tang W, Li D, Ma L, Liu H, Zhang S, Zhang X, Dong L, Shen X, Chen S, Xue R, Zhang S. Hepatic NOD2 promotes hepatocarcinogenesis via a RIP2-mediated proinflammatory response and a novel nuclear autophagy-mediated DNA damage mechanism. J Hematol Oncol. 2021;14:9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Velloso FJ, Sogayar MC, Correa RG. Expression and in vitro assessment of tumorigenicity for NOD1 and NOD2 receptors in breast cancer cell lines. BMC Res Notes. 2018;11:222.

Article  PubMed  PubMed Central  Google Scholar 

Wang Y, Miao Z, Qin X, Li B, Han Y. NOD2 deficiency confers a pro-tumorigenic macrophage phenotype to promote lung adenocarcinoma progression. J Cell Mol Med. 2021;25:7545–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Udden SMN, Peng L, Gan JL, Shelton JM, Malter JS, Hooper LV, Zaki MH. NOD2 suppresses colorectal tumorigenesis via downregulation of the TLR pathways. Cell Rep. 2017;19:2756–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu J, He C, Xu Q, Xing C, Yuan Y. NOD2 polymorphisms associated with cancer risk: a meta-analysis. PLoS ONE. 2014;9: e89340.

Article  ADS  PubMed  PubMed Central  Google Scholar 

Protti MP, De Monte L. Dual role of inflammasome adaptor ASC in cancer. Front Cell Dev Biol. 2020;8:40.

Article  PubMed  PubMed Central  Google Scholar 

Deswaerte V, Nguyen P, West A, Browning AF, Yu L, Ruwanpura SM, Balic J, Livis T, Girard C, Preaudet A, Oshima H, Fung KY, Tye H, et al. Inflammasome adaptor asc suppresses apoptosis of gastric cancer cells by an IL18-mediated inflammation-independent mechanism. Cancer Res. 2018;78:1293–307.

Article  CAS  PubMed  Google Scholar 

Liang A, Zhong S, Xi B, Zhou C, Jiang X, Zhu R, Yang Y, Zhong L, Wan D. High expression of PYCARD is an independent predictor of unfavorable prognosis and chemotherapy resistance in glioma. Ann Transl Med. 2021;9:986.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alfaro C, Sanmamed MF, Rodriguez-Ruiz ME, Teijeira A, Onate C, Gonzalez A, Ponz M, Schalper KA, Perez-Gracia JL, Melero I. Interleukin-8 in cancer pathogenesis, treatment and follow-up. Cancer Treat Rev. 2017;60:24–31.

Article  CAS  PubMed  Google Scholar 

Gonzalez-Aparicio M, Alfaro C. Significance of the IL-8 pathway for immunotherapy. Hum Vaccin Immunother. 2020;16:2312–7.

Article  CAS  PubMed  Google Scholar 

Ha H, Debnath B, Neamati N. Role of the CXCL8-CXCR1/2 axis in cancer and inflammatory diseases. Theranostics. 2017;7:1543–88.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yuen KC, Liu LF, Gupta V, Madireddi S, Keerthivasan S, Li C, Rishipathak D, Williams P, Kadel EE 3rd, Koeppen H, Chen YJ, Modrusan Z, Grogan JL, et al. High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. Nat Med. 2020;26:693–8.

Article  CAS